IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch

On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally ...
Open Heart

Intravascular haemolysis following pulsed field ablation pulmonary vein isolation for atrial fibrillation: a systematic review

Background Pulsed field ablation (PFA) has emerged as a promising non-thermal alternative to conventional atrial fibrillation ...

Congenital heart disease mutation linked to kidney damage

Biomedical engineers at Duke University have shown that a genetic mutation that causes congenital heart disease also ...

Global study finds stable acute kidney injury mortality with shifting age patterns

A five-year study has revealed a stability in global acute kidney injury (AKI)–related mortality rates with differing ...

Novo Nordisk: Long-Term Brand Dominance At A Bargain

Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.

Nuwellis, Inc.: Nuwellis Reports Third Quarter 2025 Results and Continued Operational Momentum

Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the ...